





FY2024 JAX ANNUAL REPORT

OPERATING FINANCIALS BY YEAR



ENDOWMENT VALUE BY YEAR



CONSOLIDATED BALANCE SHEETS

(in millions)

	2024	2023
ASSETS		
Cash and equivalents	\$ 29.0	17.1
Short-term investments, at fair value	221.4	217.4
Accounts receivable, net	56.6	67.0
Contributions receivable, net	20.5	27.6
Other assets	56.3	54.6
Long-term investments, at fair value	441.4	410.4
Goodwill and other intangible assets	48.7	47.6
Property, plant and equipment, net	638.0	654.0
Operating lease right-of-use assets	50.4	—
Total assets	\$ 1,562.3	1,495.7
LIABILITIES		
Accounts payable and accrued expenses	\$ 114.0	121.9
Deposits and deferred revenue	15.0	15.4
Other liabilities	15.6	15.2
Operating lease liabilities	49.1	—
Long-term debt, net	342.2	359.8
Total liabilities	535.9	512.3
Net assets	1,026.4	983.4
Total liabilities and net assets	\$ 1,562.3	1,495.7

CONSOLIDATED STATEMENTS OF ACTIVITIES & CHANGES IN NET ASSETS

(in millions)

	2024	2023
OPERATING ACTIVITIES		
<i>Revenue and other support:</i>		
Government, foundation and other grants	\$ 115.7	112.2
Philanthropic gifts	2.1	4.0
Genetic resources and clinical research services	512.3	476.7
Investment return	25.3	24.4
Other revenue	2.4	2.7
Total operating revenue	657.8	620.0
<i>Expenses:</i>		
Research	185.9	169.5
Genetic resources and clinical research services	351.3	338.2
Training	12.8	11.4
Institutional support	92.1	89.2
Total operating expenses	642.1	608.3
Change in net assets from operating activities	15.7	11.7
NON-OPERATING ACTIVITIES		
Grants and contributions for capital & long-term investments	(1.0)	(1.1)
Long-term investment return, net of amount used	29.3	32.5
Increase in net assets from non-operating activities	28.3	31.4
Other changes in net assets	(1.0)	(0.1)
Total increase in net assets	\$ 43.0	43.0